Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

This is an Open, Prospective, Single-arm Study, which is designed to evaluate the efficacy, safety and pharmacokinetics of ThisCART19A Combined With Olverembatinib for the treatment of Newly Diagnosed Ph-positive lymphoblastic leukemia.

Trial Details

NCT ID
NCT07074496
Phase
EARLY_PHASE1
Sponsor
The First Affiliated Hospital of Soochow University
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • ThisCART19A
  • Fludarabine
  • Cyclophosphamide
  • Olverembatinib
Locations (sample)
  • Suzhou, Jiangsu, China|31.30408,120.59538
  • Suzhou, Jiangsu, China|31.30408,120.59538

Key Eligibility Criteria

  • Male or non-pregnant, non-lactating female patients who are 18 years of age or older.
  • Newly diagnosed Philadelphia chromosome-positive (Ph+) or BCR-ABL1-positive ALL, as defined by the 2016-WHO criteria. Participants should not be tr…
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2, and expected survival period ≥ 3 months.
  • Organ function as indicated by the following laboratory indicators must be met:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →